https://orcid.org/0000-0001-7341-1351
References
- Zhao M, Sall Jensen M, Knudsen T, et al. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study. Aliment Pharmacol Ther. 2022;55(5):541–557.
- Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
- Raine T, Bonovas S, and Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17. DOI:10.1093/ecco-jcc/jjab178.
- EMA. Zeposia. Eur Med Agency; 2020 [cited 2022 Mar 31]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia
- Anon. FDA approves ozanimod (Zeposia) for ulcerative colitis. [cited 2021 Nov 21]. Available from: https://www.medscape.com/viewarticle/952062
- Singh S, George J, Boland BS, et al. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis. 2018;12(6):635–643.
- Danese S, Parigi TL, Peyrin-Biroulet L, et al., Defining difficult-to-treat inflammatory bowel disease: why and how. Lancet Gastroenterol Hepatol. 2021;6(7):520–522.
- Nagy G, Roodenrijs NM, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31–35.
- Ahmed W, Galati J, Kumar A, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2022;20:e361–e379. • This study reports the efficacy and safety data of dual biologic or small molecule therapy in IBD patients.
- Alayo QA, Fenster M, Altayar O, et al. Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease. Crohns Colitis. 2022;360(4):otac002.
- Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14:1385–1397.e10.
- Hong SJ, Zenger C, Pecoriello J, et al. Ustekinumab and vedolizumab are not associated with subsequent cancer in IBD Patients with prior malignancy. Inflamm Bowel Dis. 2022;izac035. 10.1093/ibd/izac035.
- D’Amico F, Parigi TL, Bonovas S, et al. Long-term safety of approved biologics for ulcerative colitis. Expert Opin Drug Saf. 2020;19(7):807–816.
- Sandborn WJ, Lawendy N, Danese S, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022;55(4):464–478.
- Fiorino G, Danese S, Pariente B, et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev. 2014;13(1):15–19.
- Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9(9):496–503.
- Wu AA, de Barros JR, Ramdeen M, et al. Factors associated with patient´S preference in choosing their therapy for inflammatory bowel disease in Brazil. Arq Gastroenterol. 2020;57(4):491–497.
- Gilardi D, Gabbiadini R, Allocca M, et al. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. Expert Rev Gastroenterol Hepatol. 2020;14(9):797–806.